ProShare Advisors
EIGR

ProShare Advisors’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History

ProShare Advisors’s Portfolio EIGR Stock Details EIGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-393
Closed -$62K – 2325
2021
Q4 		$62K Buy
393
+14
+4% +$2.71K ﹤0.01% 2261
2021
Q3 		$76K Sell
379
-101
-21% -$24K ﹤0.01% 1944
2021
Q2 		$123K Buy
480
+58
+14% +$14.5K ﹤0.01% 2262
2021
Q1 		$112K Buy
422
+29
+7% +$9.14K ﹤0.01% 2151
2020
Q4 		$145K Buy
+393
New +$113K ﹤0.01% 1927
2015
Q4 		– Sell
-41
Closed -$19K – 1728
2015
Q3 		$19K Sell
41
-1
-2% -$530 ﹤0.01% 1435
2015
Q2 		$24K Hold
42
– – ﹤0.01% 1642
2015
Q1 		$356K Buy
42
+8
+24% +$69.9K ﹤0.01% 1369
2014
Q4 		$301K Buy
+34
New +$197K ﹤0.01% 1511

Other funds holding EIGR

Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

ProShare Advisors's EIGR Position: Q1 2022 in Review

ProShare Advisors sold out of Eiger BioPharmaceuticals, Inc. (EIGR) in Q1 2022, closing a stake of 393 shares — an estimated $62K sold.

ProShare Advisors first reported a position in EIGR in Q4 2014 and held it in 9 quarters. The position peaked at $356K in Q1 2015. 94 funds tracked by Wall St. Rank hold EIGR as of Q1 2022.

  • ProShare Advisors reported no remaining Eiger BioPharmaceuticals, Inc. position as of Q1 2022 after selling out during the quarter.
  • ProShare Advisors sold 393 Eiger BioPharmaceuticals, Inc. shares in Q1 2022, an estimated $62K.
  • ProShare Advisors first reported a position in Eiger BioPharmaceuticals, Inc. in Q4 2014 and held it in 9 quarters.
  • ProShare Advisors's Eiger BioPharmaceuticals, Inc. position peaked at $356K in Q1 2015.
  • 94 funds tracked by Wall St. Rank held Eiger BioPharmaceuticals, Inc. as of Q1 2022.

Based on ProShare Advisors's 13F filing for Q1 2022, filed 10 May 2022.